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Abstract 
A catalyst-free, three-component alkylation-condensation cascade for 
spiropyran synthesis has been developed, using readily available building 
blocks (indoles, alkyl halides, salicylaldehydes) and environmentally benign 
solvents (water, ethanol). A cascade approach enables this sequence to 
proceed under mild conditions which, in turn, promote broad substrate 
tolerance and operational simplicity. Consequently, we have demonstrated 
the utility of this process in the synthesis of 25 structurally-diverse 
spiropyrans, incorporating useful functionality across the spiropyran 
framework, and on multi-gram scale.  
 
Introduction 
Dynamic functional materials have transformed the nature of contemporary 
materials science, and this technology is founded upon robust, versatile and 
tuneable molecular switches and sensors.1-3 Light-responsive spiropyrans4 
are central in this field and provide the molecular machinery upon which many 
exciting and important photoactive materials are based,5 including 
photocontrolled proteins,6-9 polymers10-12 and surfaces.13-16 
 
 
Figure 1 – Generic spiropyran-merocyanine system: (top) structure and 
properties; (bottom) as a vehicle for light control of functional molecules 
  
Despite the extensive and imaginative roles in which they have been 
employed, spiropyrans are surprisingly limited in their structural diversity. For 
example, in the research presented in Klajn’s seminal 2014 review of 
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spiropyran-based dynamic materials (covering 435 publications),5 spiropyran 
ligation is achieved almost exclusively through the indolenine nitrogen, only 
ten examples are presented in which spiropyrans bear any substituent in an 
aromatic indolenine position and every spiropyran structure includes an 
indolenine gem-dimethyl component. Whilst the function of these molecules is 
not necessarily compromised by their lack of diversity, it is entirely possible 
that spiropyran-based materials with improved, alternative, unpredicted and 
unheralded properties are not being discovered because the field is 
constrained by limitations and preconceptions in synthetic methodology for 
spiropyran synthesis. That is to say, if we have neither the tools nor the 
inclination to discover new spiropyran structures, then they are unlikely to be 
found by chance. 
 
 
Figure 2 – Standard (red) and non-standard (blue) elements in spiropyran 
structure 
 
In order to address this concern and make the opportunities that are inherent 
in new molecular architecture broadly accessible, we have focussed on the 
development of robust, simple methodologies to generate new spiropyran 
structures. Recently, we documented a microwave-promoted, one-pot, 
alkylation-condensation protocol for spiropyran synthesis from readily 
available precursors, employing environmentally benign solvents (Scheme 
1).17 The unusual substituent pattern possessed by structures such as 3 – in 
which inequivalent substituents occupy the indole 3-position – influences the 
stereoselectivity of spiropyran ring-closure and hence has relevance in the 
development of sensors for chiral substrates and asymmetric catalysts.18-20 
Moreover, the sterically-congested nature of such spiropyrans impacts upon 
spiropyran-merocyanine isomerisation and enables control of equilibrium 
position on the basis of steric effects – a complementary approach to more 




Scheme 1 – Microwave promoted alkylation-condensation in spiropyran 
synthesis.  
 
Although this alkylation-condensation methodology provided robust and rapid 
access to novel spiropyran structures, its general use is constrained by 
several limitations. Principally, methodology based around microwave 
irradiation is not universally accessible – focussed microwave facilities for 
synthetic chemistry remain specialist and expensive – and scale-up of 
microwave processes is non-trivial due to the limited penetration depth of 
microwave irradiation, often requiring flow or multimode apparatus.22-24 
Further limitations include the narrow scope of the process, its harsh 
conditions (150 °C, 200 W, sealed tube), non-ideal stoichiometry and 
dependence on silica gel chromatography for product purification. 
Furthermore, as a telescoped process employing a different solvent for each 
step, the necessity to evaporate water (the solvent for alkylation) at the mid-
point of the sequence is inconvenient and onerous. 
 
Despite these caveats, alkylation-condensation does provide a versatile and 
convenient pathway for the discovery of new spiropyran structures and we 
have explored how the potential of this synthetic strategy might be unlocked. 
Herein, we document the development of alkylation-condensation as a 3-
component cascade sequence, complementary to related spirocycle 
syntheses employing indole dearomatisation cascades.25,26 This has resulted 
in an operationally simple protocol which enables general, high-yielding 
synthesis of functionalised spiropyrans from accessible substrates, employing 
mild, catalyst-free conditions, environmentally benign solvents and short 
reaction times, and, for the majority of substrates, obviating the requirement 
for either microwave irradiation or silica gel chromatography. To demonstrate 
that this process is amenable to scale-up, we have applied this methodology 
on gram scale with no reduction in yield. 
 
Results and discussion 
The overall goal of this work was to adapt a telescoped procedure which 
employed forceful reaction conditions, into a cascade sequence with mild 
conditions and greater substrate tolerance. To realise this aim, our primary 
concern was to identify a suitable solvent system which could tolerate both 
alkylation and condensation steps, as this is a prerequisite for their successful 
application in a reaction cascade. Previous studies into alkylation-
condensation for spiropyran synthesis had identified optimal conditions as 
involving discrete synthetic steps in different solvents, with both steps 
requiring microwave irradiation in a sealed tube at 150 °C (alkylation in water: 
16 minutes; water evaporated, ethanol and nitrosalicylaldehyde added to 
reaction vessel; condensation in ethanol: 8 minutes) (see Scheme 1 and 
Table 1, entry 1).17 Our initial experimentation replicated this general protocol 
in the stepwise alkylation-condensation of 1,2,3-trimethylindole (4) with benzyl 
bromide then 5-nitrosalicylaldehyde (5) to give spiropyran 6a, as a test 
sequence for solvent screening. Polar aprotic solvents such as DMF, 
acetonitrile and acetone were ineffective, as were alcohols (entries 2-6) and 
whilst water provided a suitable medium for alkylation, subsequent 
condensation was low yielding (entry 7). Conversely, when the reaction was 
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performed in 1:1 ethanol–water, the reaction proceeded in a comparable yield 
to the optimised, microwave-promoted published process (cf. entry 1 and 
entry 8).17 This yield was unaffected by an increased aqueous component but 
was eroded by use of a higher ethanol concentration (entries 9,10), and 
acetone–water was also effective, albeit lower yielding (entry 11). With this 
key result in hand, we then repeated the same microwave-promoted protocol 
in 1:1 ethanol–water but with all reagents present from the outset (i.e. as a 
tandem process), and with a single, 10 minute heating period. Gratifyingly, 
this again produced 6a in comparably high yield (entry 12). In order to confirm 
that the role of microwave irradiation in this process was supplementary to a 
simple thermal effect, the reaction was repeated using a hotplate/oil bath, with 
reactions carried out both in a sealed tube at 150 °C and in an open vessel 
fitted with a condenser at 85 °C (entries 13 and 14). In both cases, the yield 
remained undiminished and synthesis of 6a was equally effective with or 
without microwave irradiation. This is in contrast to previous results, which 
clearly emphasise the requirement for microwave-promotion of indole 
alkylation under catalyst-free conditions.17,27  
 
Intrigued by the opportunity presented by this result, we ascertained optimal 
conditions for this process with respect to substrate stoichiometry and 
temperature, using a standard hotplate/oil bath/open vessel set-up (entries 
15-17). The previously published telescoped procedure employed an 
optimised 1:1.5:1.2 molar ratio of indole : alkylating agent : salicylaldehyde. 
By contrast, the tandem reaction described here is effective with the ideal 
1:1:1 reagent stoichiometry. In terms of reaction temperature, we observed a 
steady decline in reaction rate below 100 °C (at 50 °C, the process required 
~1 h to reach completion; at 20 °C, 6a was produced in 29% yield after 1 h), 
hence a compromise between duration and temperature is necessary 
depending on specific requirements. For our purposes, we view 1 h at 50 °C 
as a reasonable trade-off between duration, mildness and energy efficiency. 
Finally, we ensured that this protocol was effective (although somewhat 
slower) for larger scale application, through synthesis of 2.33 g (93%) of 6a in 
a single batch (entry 18).     
 
 








1e Stepwise 1.0:1.5:1.2 H2O, EtOH  150 Microwave 16 + 8 77 
2 Stepwise 1.0:1.5:1.2 DMF 150 Microwave 16 + 8 0 
3 Stepwise 1.0:1.5:1.2 MeCN 150 Microwave 16 + 8 0 
4 Stepwise 1.0:1.5:1.2 Acetone 150 Microwave 16 + 8 0 
5 Stepwise 1.0:1.5:1.2 MeOH 150 Microwave 16 + 8 0 
6 Stepwise 1.0:1.5:1.2 EtOH 150 Microwave 16 + 8 0 
7 Stepwise 1.0:1.5:1.2 H2O 150 Microwave 16 + 8 45 
8 Stepwise 1.0:1.5:1.2 1:1 H2O–EtOH 150 Microwave 16 + 8 80 
 5 
9 Stepwise 1.0:1.5:1.2 1:3 H2O–EtOH 150 Microwave 16 + 8 56 
10 Stepwise 1.0:1.5:1.2 3:1 H2O–EtOH 150 Microwave 16 + 8 78 
11 Stepwise 1.0:1.5:1.2 1:1 H2O–
acetone 
150 Microwave 16 + 8 64 
12 Tandem 1.0:1.5:1.2 1:1 H2O–EtOH 150 Microwave 10 88 
13 Tandem 1.0:1.5:1.2 1:1 H2O–EtOH 150 Oil bath
f 10 87 
14 Tandem 1.0:1.5:1.2 1:1 H2O–EtOH 85 Oil bath 10 88 
15 Tandem 1.0:1.0:1.0 1:1 H2O–EtOH 85 Oil bath 10 85 
16 Tandem 1.0:1.0:1.0 1:1 H2O–EtOH 50 Oil bath 60 86 
17 Tandem 1.0:1.0:1.0 1:1 H2O–EtOH 20 Oil bath 60 29 
18g Tandem 1.0:1.0:1.0 1:1 H2O–EtOH 50 Oil bath 110 93 
Table 1 – Optimisation of alkylation-condensation for spiropyran synthesis 
a – All reactions were performed using 4 (99 mg, 0.622 mmol, 1 eq.) in 1 mL 
of solvent. “Stepwise” refers to heating a mixture of 4, BnBr and solvent, then 
addition of 5 and subsequent heating; “tandem” infers that all reagents and 
solvent were combined then exposed to a single period of heating. b – 
Microwave heating was conducted in sealed 10 mL pressure tubes using a 
maximum power of 300 W. c – Time at the specified temperature. For 
stepwise reactions, the two given times refer to the duration of heating for 
each step.  Microwave reactions required ~30 s to reach 150 °C; oil baths 
were preheated to the specified temperature before the reaction vessel was 
immersed. d – Isolated yield. e – Taken from reference 17, with different 
solvents employed for each step. f – Reaction conducted in a sealed tube. g – 
Reaction employed 4 (1 g, 6.28 mmol). 
 
Spiropyrans are unusual and often challenging substrates for 
chromatographic purification due to isomerisation between neutral spiropyran 
and charged merocyanine forms, with this equilibrium being strongly affected 
by the dielectric of the surrounding medium. If there is a general case for 
seeking to minimise use of labour-intensive and solvent-hungry silica gel 
chromatography, it is particularly pronounced in spiropyran synthesis, and 
where possible we have employed an alternative purification method. 
Following brief experimentation, we discovered that 6a could be isolated in 
high purity and high yield, simply by precipitation of (presumably) the charged 
merocyanine isomer, by addition of acetone to the crude reaction mixture 
following concentration in vacuo. This approach provided successful 
purification of the majority of spiropyrans presented in this manuscript, though 
it was somewhat less effective with more lipophilic products. Beyond the 
operational simplicity and limited environmental impact of this protocol, it is 
immediately applicable to scale-up (as demonstrated by Table 1, entry 18), in 
contrast to the challenges presented by large-scale chromatography.28 
  
With mild, efficient and operationally simple conditions identified, we 
determined the scope of our three-component reaction cascade in the 
synthesis of a range of spiropyran structures. In general, broad substrate 
tolerance was exhibited by the reaction sequence towards each of the three 
components (indole, alkylating agent, salicylaldehyde). The greatest impact 
on scope was observed in substituents that directly influenced indole 
alkylation, whilst the salicylaldehyde condensation was generally more 
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accommodating. Accordingly, indole components incorporating varied N- or 
benzenoid substituents were generally successful substrates (Table 2, 6b-f), 
with the exception of N-acetate 6z which underwent decarboxylation to give 
6a, presumably via azomethine ylid formation,29,30 whereas substituents in the 
3-position presented varied outcomes: alkyl, branched alkyl, aryl, benzyl and 
carboxyl substituents were effective (6g-k); whereas the presence of a 3-
formyl substituent (6aa) lead to a complex mixture of products and, although a 
3-acetyl moiety could be incorporated into spiropyran 6ab, this underwent 
decarboxylative degradation (analogous to natural31,32 and synthetic33 
decarboxyation processes) and could not be isolated in acceptable purity. 
Appropriate alkylating agents for this process were strictly defined by steric 
inflences on one hand and electronics on the other. In general, “classical” 
primary substrates for nucleophilic substitution could be successfully 
incorporated into spiropyran products (e.g. benzyl, allyl, propargyl, phenacyl 
(6l-p)); however, quaternisation imposes steric demands, and secondary and 
tertiary alkylating agents were unreactive (e.g. α-phenylbenzyl, α-
methylbenzyl and tbutyl spiropyrans 6ac-ae could not be synthesised). 
Nevertheless, spiropyrans 6h (iPr/Bn), 6i (4-BrPh/Bn) and 6j (Bn/Bn) 
demonstrate the power of this methodology to deliver particularly congested 
structures. Mechanistically, indole alkylation in polar protic media is 
predominantly an SN1 process.
17,27 Consequently, only the most active SN2 
electrophiles were tolerated (e.g. α-bromocarbonyl), and even primary alkyl 
halides were ineffective substrates (e.g. 6af was inaccessible via this 
procedure). 
 
The reaction sequence displayed general tolerance for salicylaldehydes, 
hence a range of functional groups – possessing contrasting electronic 
character – could be incorporated into the spiropyran chromene ring in any 
position (6q-y). Reactions of electron-rich salicylaldehydes were 
comparatively slow (e.g. synthesis of methoxyspiropyran 6s required 6 h), 
consistent with their reduced aldehyde electrophilicity, and, somewhat 
surpisingly, salicylaldehyde itself proved to be a singularly reluctant 
electrophile. In this case, a reasonable yield of spiropyran 6q was only 



































































6g, 81% (2.5 h)a
6q, 7% (22 h); 64%a,c
6v, 65% (4 h)b 6x, 87% (1.5 h)b
6s, 91% (6 h)b
6h, 72% (4 h)a
6l, 81% (1 h)b 6m, 78% (1 h)b6j, 80% (4 h)a
6u, 83% (1 h)b
6w, 59% (4 h)b
6p, 76% (3 h)a
6i, 58% (5 h)b
6t, 93% (6 h)a
6y, 83% (1 h)b
6n, 72% (2 h)b
6k, 61% (3 h)a
6r, 73% (26 h)a
6c, 79% (1 h)a6b, 68% (1.5 h)a 6d, 86% (2 h)b
6f, 78% (1 h)b
6e, 75% (1.5 h)b



































6ac; R = Ph2CH 6ad; R = Ph(Me)CH
6ae; R = tBu 6af; R = nHexyl
 
Table 2 – Scope of tandem alkylation-condensation. All reactions conducted 
at 0.622 M and 1:1:1 reagent stoichiometry. Yields refer to isolated products. 
Reaction times are given in parentheses. Attempted synthesis of 6z-6af 
(bottom) was not successful using this procedure. a – purified by silica gel 
chromatography; b – purified by precipitation from acetone; c – reaction 
employed 3 eq. salicylaldehyde and microwave irradiation (150 °C, 15 mins, 
300 W max.) 
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The placement and variety of substituents that we have included to 
demonstrate the versatility of this alkylation-condensation cascade is very 
deliberate. Firstly, we have focussed on incorporating substituents in positions 
that are known to influence spiro-mero equilibration, hence giving control and 
tunability to spiropyran products in this fundamental property. This is achieved 
either electronically, through stabilisation/destabilisation of the merocyanine 
phenoxide and iminium moieties34,35 – hence we have demonstrated control 
over all benzenoid chromene positions (i.e. 6q-6y) and the indole 5-position 
(6e,f) respectively‡ – or by exerting steric control through incorporation of 
large substituents in the indole 3-position (e.g. 6h-k). Secondly, we have 
synthesised derivatives bearing groups with a large difference in size in the 
indole 3-position (e.g. 6m,p), as this has been previously demonstrated to 
influence facial discrimination in spiropyran ring closure, and this is of 
relevance to the design of sensors for chiral substrates.17 Thirdly, we have 
included examples bearing extended π-conjugation (benzoindole 6d and 
benzochromene 6r) to exhibit that this methodology is appropriate for 
generating structures possessing red-shifted absorbance maxima.34,37 This is 
an important consideration both conceptually, in that control over the mero-
spiro switching wavelength is desirable, and biomedically, in that the greater 
tissue penetration offered by near IR is important for in vivo application.38 
Fourthly, a majority of important spiropyran applications involve ligation of 
spiropyran units onto polymers, biopolymers or surfaces, or construction of 
bespoke binding sites around the spiropyran core for specific ligands.5 The 
success of either approach is underpinned by synthetic versatility and this is a 
principal virtue of tandem alkylation-condensation. We have demonstrated 
this by synthesis of spiropyrans bearing useful handles for further synthetic 
transformations, in a variety of positions. This includes substrates for click 
chemistry (6b,o), alkene metathesis (6c,n), palladium-catalysed cross-
couplings (6e,i,m,v-y), standard carbonyl chemistry (6p) and ester linkage 
(6k,u). Finally, we have synthesised several spiropyrans which are 
inaccessible using our previous telescoped methodology, to exhibit that a 
cascade sequence in an accommodating solvent system with mild conditions 
has greater substrate tolerance than the more forcing conditions that 
preceded it. This includes arylspiropyran 6i, ethylcarboxylate 6k and 
dibenzylspiropyran 6j.  
 
It is striking that simply through identification of an appropriate solvent system 
and adoption of a cascade approach, we have been able to generate an 
effective, convenient, mild protocol, far removed from its genesis as a 
microwave-promoted telescoped procedure. Underpinning this drastic 
improvement are two key factors: (i) The requirement for water in the 
alkylation step might suggest that on-water reactivity is relevant, particularly in 
a process employing profoundly hydrophobic indole and alkyl bromide 
substrates.39,40 On the other hand, it is plausible that water is necessary to 
stabilise charge in SN1 transition states and indolium bromide salt products. 
We favour this latter hypothesis, given that the reaction only appears to 
become viable when efforts are made to solubilise these hydrophobic 
                                            
‡
 It is also of interest that substituents in this position prevent oxidative spiropyran 




reagents, rather than force them into on-water behaviour. In the telescoped 
process, a degree of solubilisation is provided by the reduced polarity of water 
at 150 °C in a sealed system,41 whereas a similar effect can be achieved by 
addition of ethanol under a considerably milder regime.  
(ii) Synthesis of indolium salts by alkylation of 3-substituted indoles constitutes 
an electronically and sterically challenging dearomatising quaternisation. In 
contrast, the condensation of indolium salts with salicylaldehydes is 
thermodynamically driven by generation of stabilised, conjugated 
merocyanines. Consequently, conducting indole alkylation in the presence of 
a salicylaldehyde enables rapid reaction of intermediate indolium salts, 
thereby driving an otherwise unfavourable alkylation process towards 
completion. Clearly, this accelerative effect is absent in the comparative 
telescoped sequence.  
Overall, the unfavourable alkylation is made possible under mild conditions by 
transition state and intermediate stabilisation by water, and by rapid 
consumption of its indolium product by salicylaldehyde which occurs most 
effectively in the presence of ethanol.  The summative consequence of these 
effects is that cascade alkylation-condensation can proceed at 50 °C without 
excess alkylating agent, whereas the analogous telescoped process cannot. 
 
Whilst the focus of this study was to develop efficient methodology for 
spiropyran synthesis, products 6a-y present interesting stereochemical 
features, worthy of comment here. In solution, spiropyran diastereomers exist 
in dynamic equilibrium, interconverting via their merocyanine form (Figure 3). 
We have previously reported that assignment of spiropyran relative 
configuration can be achieved using NOESY analysis and diastereoisomeric 
ratios can be estimated by 1H NMR.17 Our previous analysis demonstrated a 
bias for anti-configured structures, in which larger substituents on the indole 
3-position were placed to minimise interaction with the chromene oxygen 
atom, with the exception of carbonyl-containing substituents wherein this 
trend was reversed.17 In this study, we have observed a similar general trend 
for anti-selectivity with similar magnitude (in the range syn:anti 25:75 to 
33:67), and similar syn-configured exceptions wherein interactions between 
carbonyl and alkene functionalities are minimised (6k and 6p). 
 
 
Figure 3 – Interconversion between syn and anti spiropyran diastereomers 
via a merocyanine isomer, illustrated by compound 6q. Transient cis-
merocyanine forms are omitted for brevity. Diagnostic NOESY correlations 
are depicted in blue.  
 
Conclusion 
In summary, we have designed, optimised and road-tested a catalyst-free, 
three-component alkylation-condensation cascade for spiropyran synthesis 
from cheap, accessible building blocks (indoles, alkylating agents, 
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salicylaldehydes). The reaction sequence is operationally simple, employs 
mild conditions, environmentally benign solvents, short reaction times and 
ideal stoichiometry, and generates useful spiropyran products in generally 
high yield, often with no requirement for chromatographic purification. The 
process demonstrates broad substrate tolerance and enables incorporation of 
substituents that influence fundamental spiropyran properties (spiro-mero 
equilibrium, absorbance wavelength, facial selectivity) in most possible 
positions, and incorporation of versatile functional groups (alkene, alkyne, aryl 
halide, ester, ketone) for subsequent synthetic transformations. In terms of 
synthetic strategy and design, this tandem alkylation-condensation sequence 
epitomises the value of a well-designed reaction cascade over an analogous 
telescoped, stepwise process, with impacts upon operational simplicity, 
mildness of conditions and breadth of substrate scope. Given the simplicity 
and versatility of this methodology, we anticipate that it will underpin the 
design and synthesis of novel spiropyran architectures and their application in 
future dynamic materials. 
 
Experimental 
General Experimental Information 
Solvents and reagents were used as commercially supplied. The fraction of 
light petroleum ether boiling in the range 40 to 60 °C is referred to as “petrol”. 
Water refers to deionised water. Analytical thin layer chromatography was 
carried out using Merck Kieselgel 60 F254, coated on aluminium plates, with 
visualisation of spots where necessary by quenching of UV(254 nm) 
fluorescence. Silica gel with particle size 40–63 mm was used for flash 
chromatography. Microwave reactions were performed in a CEM Discover 
microwave in 10 mL, thick-walled microwave tubes, sealed with septum caps 
and were magnetically stirred. Infrared spectra were recorded as thin films 
using attenuated total reflectance with a Nicolet iS5 FTIR spectrometer. Mass 
spectra were recorded on a QToF 6520 mass spectrometer (Agilent 
Technologies, Palo Alto, USA). 1H NMR and 13C NMR spectra were recorded 
at 400 MHz and 100 MHz respectively, using a Bruker Avance III HD400 
spectrometer. Chemical shifts are quoted in ppm relative to tetramethylsilane, 
the residual solvent peak being used for referencing purposes. Coupling 
constants are quoted to the nearest 0.1 Hz with peak multiplicities for single 
resonances being labelled as: s, singlet; d, doublet; t, triplet; q, quartet; m, 
unresolved multiplet. NMR assignments of spiropyrans and merocyanines are 
labelled as follows (using 6a as an example): 
 
 
For simplicity, spiropyran atom labelling has been retained in merocyanine 
structures. The compounds documented in this publication exist in solution as 
equilibrating mixtures of spiropyran diastereoisomers which interconvert via 
their merocyanine form. The merocyanines themselves can exist as 
zwitterionic, protonated or quinoidal forms. Although interpretation of NMR 
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spectra from such multicomponent mixtures is challenging due to overlapping 
resonances and broadened signals from charged species, and full analysis is 
occasionally impossible, we have sought to assign nuclei as far as we can 
within reasonable doubt and merocyanine:syn:anti ratios are quoted for NMR 
spectra as appropriate. 2D NOESY experiments were used – and proved 
invaluable – for assignment of 1H NMR spectra and for determination of 
relative configurations. In general, 13C NMR spectra have been fully assigned 
and this has been achieved through use of HSQC and HMBC experiments. 
 
Synthetic Methods and Characterisation Data 
Example procedure for spiropyran synthesis: 
3-Benzyl-1,3-dimethyl-6′-nitrospiro[chromene-2,2'-indoline]17 6a 
A stirred mixture of 1,2,3-trimethylindole (99.0 mg, 0.622 mmol), benzyl 
bromide (74.0 µL, 0.622 mmol) and 5-nitrosalicylaldehyde (104 mg, 0.622 
mmol) in ethanol–water (1 mL, 1:1 v:v) was heated at 50 °C for 1 h then 
concentrated under reduced pressure. Acetone (10 mL) was added to the 
crude reaction mixture and the resulting precipitate was filtered, washing with 
acetone, to give spiropyran 6a (213 mg, 86%) as a yellow powder, 
spectroscopically identical to that previously reported.17  
 
Reaction on gram-scale: 
Following the same general method, a mixture of 1,2,3-trimethylindole (1.00 g, 
6.28 mmol), benzyl bromide (746 µL, 6.28 mmol) and 5-nitrosalicylaldehyde 
(1.05 g, 6.28 mmol) in ethanol–water (10.1 mL, 1:1 v:v) was heated for 110 





Following the same general method, 2,3-dimethyl-1-propargylindole (95.0 mg, 
0.518 mmol), benzyl bromide (62.0 µL, 0.518 mmol) and 5-
nitrosalicylaldehyde (87.0 mg, 0.518 mmol) were heated for 1.5 h to give 
spiropyran 6b (148 mg, 68%) as an amorphous purple film (purified by flash 
chromatography, eluting with EtOAc, then 10% MeOH in EtOAc, then 20% 
MeOH in EtOAc). νmax = 3290, 3029, 2933, 1707, 1512, 1495, 1336, 1292, 
1148, 949 and 746 cm–1; δH (400 MHz; DMSO-d6; 25:75 syn:anti) 8.26 (1 H, 
d, J 2.8, 5'-H anti), 8.19 (1 H, d, J 2.8, 5'-H syn), 8.09 (1 H, dd, J 9.0, 2.8, 7'-H 
syn), 8.00 (1 H, dd, J 9.0, 2.8, 7'-H anti), 7.33 (1 H, d, J 10.4, 4'-H anti), 7.22 – 
7.10 (7 H, m, 4-, 6-, Bn 4-H syn; 6-, Bn 3,4,5-H anti), 7.07 (2 H, t, J 7.2, Bn 
3,5-H syn), 7.01 (2 H, d, J 7.2, Bn 2,6-H syn), 7.00 (1 H, d, J 9.0, 8'-H syn), 
6.97 (1 H, d, J 10.3, 4'-H syn), 6.87 (1 H, t, J 7.5, 5-H syn), 6.83 (1 H, d, J 7.5, 
7-H anti), 6.82 (1 H, d, J 9.0, 8'-H anti), 6.72 (1 H, d, J 7.5, 7-H syn), 6.66 – 
6.61 (3 H, m, 5-, Bn 2,6-H anti), 6.20 (1 H, d, J 10.4, 3'-H anti), 6.06 (1 H, d, J 
7.5, 4-H anti), 5.70 (1 H, d, J 10.3, 3'-H syn), 4.20 (1 H, dd, J 18.3, 2.3, NCHH 
anti), 4.00 (1 H, dd, J 18.3, 2.3, NCHH syn), 3.92 (1 H, dd, J 18.3, 2.3, NCHH 
anti), 3.69 (1 H, dd, J 18.3, 2.3, NCHH syn), 3.22 (1 H, d, J 13.5, Bn CHH 
syn), 3.14 (1 H, d, J 13.5, Bn CHH syn), 2.99 (1 H, t, J 2.3, ≡CH anti), 2.87 (1 
H, t, J 2.3, ≡CH syn), 2.78 (1 H, d, J 12.4, Bn CHH anti), 2.58 (1 H, d, J 12.4, 
Bn CHH anti), 1.18 (3 H, s, Me syn) and 1.12 (3 H, s, Me anti); δC (100 MHz; 
DMSO-d6); anti diastereoisomer: 159.5 (8a'), 146.4 (7a), 141.0 (6'), 136.9 (Bn 
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1), 132.1 (3a), 131.7 (Bn 2,6), 129.8 (4'), 128.3 (6), 127.7 (Bn 3,5), 126.8 (Bn 
4), 126.3 (7'), 124.9 (4), 123.4 (5'), 121.2 (3'), 119.1 (4a'), 119.0 (5), 116.2 (8'), 
108.5 (7), 107.3 (2), 80.7 (C≡CH), 74.4 (C≡CH), 57.3 (3), 41.6 (Bn CH2), 32.4 
(NCH2) and 16.6 (3-Me); syn diastereoisomer: 158.9 (8a'), 144.9 (7a), 141.0 
(6'), 137.6 (Bn 1), 136.2 (3a), 130.0 (Bn 2,6), 128.2 (6), 128.1 (4'), 127.9 (Bn 
3,5), 126.8 (Bn 4), 126.0 (7'), 123.2 (5'), 122.6 (4), 120.4 (3'), 120.3 (5), 119.3 
(4a'), 117.0 (8'), 108.5 (7), 104.0 (2), 80.5 (C≡CH), 74.3 (C≡CH), 54.8 (3), 
38.8 (Bn CH2), 31.0 (NCH2) and 24.3 (3-Me); HRMS-ES+ (m/z): Found:  




Following the same general method, 1-allyl-2,3-dimethylindole (115 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-nitrosalicylaldehyde (104 
mg, 0.622 mmol) were heated for 1 h to give spiropyran 6c (209 mg, 79%) as 
an amorphous purple film (purified by flash chromatography, eluting with 
EtOAc, then 10% MeOH in EtOAc, then 20% MeOH in EtOAc). νmax = 3028, 
2967, 2923, 1711, 1608, 1516, 1479, 1332, 1266, 1087, 945, 803, 746 and 
702 cm–1; δH (400 MHz; DMSO-d6; 40:20:40 MC:syn:anti) 9.08 (1 H, d, J 2.8, 
MC 5'-H), 8.71 (1 H, d, J 16.2, MC 4'-H), 8.25 (1 H, dd, J 9.2, 2.8, MC 7'-H), 
8.22 (1 H, d, J 2.8, 5'-H anti), 8.16 (1 H, d, J 2.7, 5'-H syn), 8.11 (1 H, d, J 7.5, 
MC 4-H), 8.06 (1 H, dd, J 8.8, 2.7, 7'-H syn), 8.04 (1 H, d, J 16.2, MC 3'-H), 
7.97 (1 H, dd, J 9.0, 2.8, 7'-H anti), 7.67 (1 H, d, J 7.5, MC 7-H), 7.66 (1 H, t, J 
7.5, MC 5-H), 7.57 (1 H, t, J 7.5, MC 6-H), 7.28 (1 H, d, J 10.4, 4'-H anti) 7.18 
– 6.90 (17 H, m, MC Bn 3,4,5-, 8'-H; Bn 2,3,4,5,6-, 4-, 4'-, 8'-, 6-H syn; Bn 
3,4,5-, 6-H anti), 6.82 (1 H, d, J 9.0, 8'-H anti), 6.77 (1 H, t, J 7.5, 5-H syn), 
6.60 (2 H, d, J 7.0, Bn 2,6-H anti), 6.58 (1 H, t, J 7.5, 5-H anti), 6.57 (1 H, d, J 
7.5, 7 anti), 6.52 (1 H, t, J 7.4, MC Bn 2,6-H), 6.49 (1 H, d, J 7.5, 7-H syn), 
6.17 (1 H, d, J 10.4, 3'-H anti), 6.09 (1 H, d, J 7.5, 4-H anti), 5.88 – 5.77 (1 H, 
m, allyl 2-H anti), 5.73 (1 H, d, J 10.3, 3'-H syn), 5.73 – 5.65 (1 H, m, allyl 2-H 
syn), 5.58 – 5.47 (1 H, m, MC allyl 2-H), 5.16 – 4.94 (7 H, m, MC allyl 1,3-H; 
allyl 3-H syn; allyl 3-H anti), 4.43 (1 H, d, J 17.3, MC allyl 3-H), 3.93 – 3.88 (1 
H, m, allyl 1-H anti), 3.88 (1 H, d, J 13.5, MC PhCHH), 3.82 (1 H, d, J 13.5, 
MC PhCHH), 3.66 (2 H, dd, J 17.1, 5.3, allyl 1-H syn; allyl 1-H anti), 3.50 (1 H, 
dd, J 17.1, 5.3, allyl 1-H syn), 3.20 (1 H, d, J 13.5, PhCHH syn), 3.09 (1 H, d, 
J 13.5, PhCHH syn), 2.78 (1 H, d, J 12.5, PhCHH anti), 2.62 (1 H, d, J 12.5, 
PhCHH anti), 1.98 (3 H, s, MC 3-Me), 1.20 (3 H, s, 3-Me syn) and 1.11 (3 H, 
s, 3-Me anti); δC (100 MHz; DMSO-d6); merocyanine: 181.6 (C=N), 167.8 
(8a'), 150.2 (4'), 142.0 (3a), 141.8 (7a), 139.3 (6'), 134.9 (Bn 1), 129.9 (7'), 
129.7 (6), 129.6 (5'), 129.6 (5), 129.4 (allyl 2), 129.3 (Bn 2,6), 128.4 (Bn 3,5), 
128.3 (Bn 4), 124.6 (4), 121.9 (4a'), 119.4 (8'), 119.0 (allyl 3), 115.4 (7), 114.8 
(3'), 58.6 (3), 49.3 (allyl 1), 45.8 (PhCH2) and 25.8 (3-Me); anti 
diastereoisomer: 159.6 (8a'), 147.5 (7a), 141.0 (6'), 137.0 (Bn 1), 135.3 (allyl 
2), 132.0 (3a), 131.6 (Bn 2,6), 129.3 (4'), 127.7 (Bn 4), 127.6 (Bn 3,5), 126.7 
(6), 126.3 (7'), 124.6 (4), 123.5 (5'), 121.9 (3'), 119.2 (4a'), 118.4 (5), 116.4 
(allyl 3), 116.0 (8'), 107.9 (2), 107.8 (7), 57.5 (3), 46.2 (allyl 1), 41.9 (PhCH2) 
and 17.0 (3-Me); syn diastereoisomer: 158.8 (8a'), 146.0 (7a), 141.0 (6'), 
137.7 (Bn 1), 136.0 (3a), 135.0 (allyl 2), 131.1 (Bn 2,6), 128.1 (Bn 4), 127.9 
(Bn 3,5), 127.7 (6), 126.1 (7'), 123.2 (5'), 122.6 (4), 121.1 (3'), 119.6 (5), 119.5 
(4a'), 116.4 (8'), 116.4 (allyl 3), 107.8 (7), 104.6 (2), 54.8 (3), 44.8 (allyl 1), 
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38.9 (PhCH2) and 24.6 (3-Me); HRMS-ES+ (m/z): Found:  425.1885 (MH
+, 




Following the same general method, 1,2,3-trimethylbenzo[e]indole (130 mg, 
0.622 mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 2 h to give 
spiropyran 6d (240 mg, 86%) as an orange powder (purified by precipitation 
from acetone). νmax = 2942, 1610, 1540, 1520, 1493, 1440, 1342, 1287, 1262, 
1230, 1085, 959, 810, 745, 703 and 637 cm–1; δH (400 MHz; DMSO-d6) 9.15 
(1 H, s, 5'-H), 8.71 – 8.67 (2 H, m, 4- and 4'-H), 8.35 (1 H, d, J 8.0, 7'-H), 8.22 
(2 H, d, J 7.5, 7- and 8-H), 8.09 (1 H, d, J 16.3, 3'-H), 7.91 – 7.88 (2 H, m, 5- 
and 9-H), 7.79 (1 H, br t, J 7.5, 6-H), 7.26 (1 H, d, J 8.0, 8'-H), 7.01 – 6.90 (3 
H, m, Bn 3,4,5-H), 6.40 (2 H, d, J 7.0, Bn 2,6-H), 4.22 (1 H, d, J 13.3, CHH), 
4.15 (3 H, s, NMe), 4.04 (1 H, d, J 13.3, CHH) and 2.20 (3 H, s, 3-Me); δC 
(100 MHz; DMSO-d6) 182.2 (C=N), 164.6 (8a'), 146.8 (4'), 140.7 (9a), 140.5 
(6'), 136.7 (3a), 134.6 (Bn 1), 133.6 (7a), 131.9 (8), 130.6 (7), 129.8 (7'), 
129.2 (5), 128.3 (Bn 2,6), 128.3 (Bn 3,5), 128.3 (4a), 128.0 (6), 127.7 (Bn 4), 
127.6 (5'), 124.1 (4), 122.1 (4a'), 117.9 (8'), 115.7 (3'), 113.3 (9), 60.5 (3), 
45.5 (CH2), 35.5 (NMe) and 24.9 (3-Me); HRMS-ES+ (m/z): Found:  449.1882 




Following the same general method, 5-bromo-1,2,3-trimethylindole (148 mg, 
0.622 mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 1.5 h to give 
spiropyran 6e (222 mg, 75%) as a yellow powder (purified by precipitation 
from acetone). νmax = 2931, 2777, 2690, 2566, 1738, 1619, 1607, 1584, 1548, 
1473, 1348, 1288, 1266, 1226, 1084, 821, 744 and 705 cm–1; δH (400 MHz; 
DMSO-d6) 9.18 (1 H, d, J 2.7, 5'-H), 8.69 (1 H, d, J 16.5, 4'-H), 8.41 (1 H, dd, 
J 9.1, 2.7, 7'-H), 8.31 (1 H, d, J 1.7, 4-H), 8.06 (1 H, d, J 16.6, 3'-H), 7.87 (1 H, 
dd, J 8.6, 1.7, 6-H), 7.76 (1 H, d, J 8.6, 7-H), 7.32 (1 H, d, J 9.1, 8'-H), 7.16 – 
7.10 (3 H, m, Bn 3,4,5-H), 6.74 (2 H, d, J 6.5, Bn 2,6-H), 3.93 (3 H, s, NMe), 
3.79 (1 H, d, J 13.9, CHH), 3.75 (1 H, d, J 13.9, CHH) and 1.96 (3 H, s, 3-Me); 
δC (100 MHz; DMSO-d6) 181.7 (C=N), 164.8 (8a'), 148.8 (4'), 143.8 (3a), 
141.9 (7a), 140.7 (6'), 134.7 (Bn 1), 132.7 (6), 130.1 (7'), 129.3 (Bn 2,6), 
128.4 (Bn 3,5), 128.2 (5'), 127.8 (Bn 4), 127.7 (4), 123.2 (5), 121.9 (4a'), 
117.9 (8'), 117.3 (7), 116.1 (3'), 58.6 (3), 45.5 (CH2), 35.0 (NMe) and 24.6 (3-






Following the same general method, 1,2,3,5-tetramethylindole (108 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-nitrosalicylaldehyde (104 
mg, 0.622 mmol) were heated for 1 h to give spiropyran 6f (201 mg, 78%) as 
a yellow powder (purified by precipitation from acetone). νmax = 3027, 2777, 
2692, 2567, 1736, 1622, 1610, 1585, 1556, 1517, 1442, 1348, 1289, 1262, 
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1229, 1126, 1084, 969, 838, 817, 762, 745 and 703 cm–1; δH (400 MHz; 
DMSO-d6) 9.11 (1 H, d, J 2.8, 5'-H), 8.58 (1 H, d, J 16.6, 4'-H), 8.34 (1 H, dd, 
J 9.2, 2.8, 7'-H), 7.98 (1 H, d, J 16.6, 3'-H), 7.77 (1 H, s, 4-H), 7.64 (1 H, d, J 
8.2, 7-H), 7.41 (1 H, d, J 8.2, 6-H), 7.28 (1 H, d, J 9.2, 8'-H), 7.10 – 7.01 (3 H, 
m, Bn 3,4,5-H), 6.64 (2 H, d, J 6.9, Bn 2,6-H), 3.92 (3 H, s, NMe), 3.74 (2 H, s, 
CH2), 2.50 (3 H, s, 5-Me) and 1.92 (3 H, s, 3-Me); δC (100 MHz; DMSO-d6) 
180.4 (C=N), 164.6 (8a'), 147.2 (4'), 141.9 (3a), 140.7 (7a), 140.6 (6'), 140.4 
(5), 134.9 (Bn 1), 130.3 (6), 129.8 (7'), 129.3 (Bn 2,6), 128.4 (Bn 3,5), 127.9 
(5'), 127.7 (Bn 4), 124.9 (4), 122.0 (4a'), 117.9 (8'), 116.3 (3'), 115.2 (7), 58.2 
(3), 45.6 (CH2), 34.9 (NMe), 25.0 (3-Me) and 21.7 (5-Me); HRMS-ES+ (m/z): 




Following the same general method, 1,2-dimethyl-3-ethylindole (108 mg, 
0.622 mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 2.5 h to give 
spiropyran 6g (208 mg, 81%) as an amorphous purple film (purified by flash 
chromatography, eluting with EtOAc, then 50% MeOH in EtOAc), 




Following the same general method, 1,2-dimethyl-3-isopropylindole (116 mg, 
0.622 mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 4 h to give 
spiropyran 6h (191 mg, 72%) as an amorphous purple film (purified by flash 
chromatography, eluting with EtOAc, then 5% MeOH in EtOAc, then 10% 
MeOH in EtOAc). νmax = 2969, 1738, 1652, 1597, 1455, 1411, 1283, 1216, 
1023, 990, 826 and 698 cm–1; δH (400 MHz; DMSO-d6) 8.79 (1 H, d, J 3.1, 5'-
H), 8.65 (1 H, d, J 15.2, 4'-H), 8.43 (1 H, d, J 15.2, 3'-H), 7.93 (1 H, d, J 7.5, 4-
H), 7.86 (1 H, dd, J 9.7, 3.1, 7'-H), 7.60 – 7.50 (3 H, m, 5-, 6-, 7-H), 6.99 – 
6.85 (3 H, m, Bn 3,4,5-H), 6.54 (2 H, d, J 7.0, Bn 2,6-H), 6.34 (1 H, d, J 9.7, 
8'-H), 3.65 (2 H, s, CH2), 3.39 (3 H, s, NMe), 2.60 – 2.49 (1 H, m, HCMe2), 
1.16 (3 H, d, J 6.6, CMe) and 0.08 1.16 (3 H, d, J 6.6, CMe); δC (100 MHz; 
DMSO-d6) 181.1 (C=N), 180.4 (8a'), 154.9 (4'), 144.1 (7a), 136.6 (3a), 136.2 
(Bn 1), 134.9 (5'), 132.5 (6'), 129.7 (6), 129.1 (Bn 2,6), 128.8 (7'), 128.2 (Bn 
3,5), 127.2 (5), 127.2 (Bn 4), 125.8 (4), 125.2 (8'), 121.7 (4a'), 113.7 (7), 108.3 
(3'), 65.6 (3), 42.1 (CH2), 39.1 (CMe2), 33.0 (NMe), 18.4 (CMe) and 17.6 






Following the same general method, 3-(4-bromophenyl)-1,2-dimethylindole 
(187 mg, 0.622 mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 5 h to give 
spiropyran 6i (195 mg, 58%) as an orange powder (purified by precipitation 
from acetone). νmax = 2683, 1734, 1602, 1517, 1490, 1336, 1289, 1262, 1077, 
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975, 749 and 700 cm–1; δH (400 MHz; DMSO-d6) 9.04 (1 H, d, J 2.7, 5'-H), 
8.29 (1 H, dd, J 9.2, 2.7, 7'-H), 8.04 (1 H, d, J 17.0, 4'-H), 8.00 (1 H, d, J 17.0, 
3'-H), 7.75 – 7.55 (6 H, m, 4-, 5-, 6-, 7-, 3''- and 5''-H), 7.50 (2 H, d, J 8.5, 2''-, 
6''-H), 7.12 (1 H, d, J 9.2, 8'-H), 7.10 (1 H, d, J 7.3, Bn 4-H), 7.01 (2 H, t, J 7.3, 
Bn 3,5-H), 6.54 (2 H, d, J 7.3, Bn 2,6-H), 4.42 (1 H, d, J 12.7, CHH), 3.98 (1 
H, d, J 12.7, CHH) and 3.94 (3 H, s, NMe); δC (100 MHz; DMSO-d6) 180.4 
(C=N), 164.5 (8a'), 149.1 (4'), 142.6 (7a), 141.8 (3a), 140.7 (6'), 138.1 
(4''),133.1 (Bn 1), 132.8 (3'',5''), 130.5 (5), 130.5 (6), 130.2 (7'), 129.7 (2'',6''), 
129.5 (Bn 2,6), 128.2 (Bn 3,5), 128.0 (Bn 4), 126.1 (5'), 124.9 (4), 122.6 (1''), 
121.7 (4a'), 117.8 (8'), 115.8 (7), 114.7 (3'), 64.9 (3), 44.3 (CH2) and 35.0 






Following the same general method, 3-benzyl-1,2-dimethylindole (172 mg, 
0.731 mmol), benzyl bromide (87.0 µL, 0.731 mmol) and 5-
nitrosalicylaldehyde (122 mg, 0.731 mmol) were heated for 4 h to give 
spiropyran 6j (235 mg, 80%) as an amorphous purple film (purified by flash 
chromatography, eluting with EtOAc, then 50% MeOH in EtOAc). νmax = 2975, 
1601, 1520, 1494, 1455, 1337, 1286, 1081, 979, 830, 747 and 700 cm–1; δH 
(400 MHz; DMSO-d6) 9.06 (1 H, d, J 2.8, 5'-H), 8.83 (1 H, d, J 16.1, 4'-H), 
8.21 (1 H, d, J 16.1, 3'-H), 8.19 (1 H, dd, J 9.1, 2.8, 7'-H), 8.09 (1 H, d, J 7.6, 
4-H), 7.63 – 7.59 (1 H, m, 5-H), 7.49 – 7.45 (2 H, m, 6-, 7-H), 7.07 – 6.95 (7 
H, m, 8'-, Bn 3,4,5-H), 6.66 (4 H, d, J 6.9, Bn 2,6-H), 3.98 (4 H, s, 2 × CH2) 
and 3.62 (3 H, s, NMe); δC (100 MHz; DMSO-d6) 179.5 (C=N), 171.0 (8a'), 
151.5 (4'), 143.1 (7a), 139.2 (3a), 137.9 (6'), 134.5 (Bn 1), 130.8 (5'), 130.0 
(6), 129.7 (7'), 129.4 (Bn 2,6), 129.0 (5), 128.4 (Bn 3,5), 127.6 (Bn 4), 125.4 
(4), 122.0 (4a'), 120.6 (8'), 114.6 (7), 114.0 (3'), 64.1 (3), 44.9 (CH2) and 34.1 






Following the same general method, ethyl 1,2-dimethylindole-3-carboxylate 
(135 mg, 0.622 mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 3 h to give 
spiropyran 6k (173 mg, 61%) as an amorphous purple film (purified by flash 
chromatography, eluting with EtOAc, then 50% MeOH in EtOAc). νmax = 3036, 
2794, 1743, 1600, 1548, 1486, 1470, 1442, 1377, 1339, 1258, 1218, 1167, 
1132, 1089, 1045, 972, 858, 744 and 696  cm–1; δH (400 MHz; DMSO-d6; 
83:17 MC:syn) 9.14 (1 H, s, MC 5'-H), 8.36 (1 H, d, J 8.0, MC 7'-H), 8.35 (1 H, 
d, J 16.4, MC 4'-H), 8.34 (1 H, s, 5'-H syn), 8.12 (1 H, d, J 16.4, MC 3'-H), 
7.99 (1 H, d, J 8.3, 7'-H syn), 7.94 (1 H, d, J 6.5, MC 4-H), 7.77 (1 H, d, J 6.5, 
MC 7-H), 7.71 (1 H, t, J 7.5, MC 5-H), 7.70 (1 H, t, J 7.5, MC 6-H), 7.34 (1 H, 
d, J 10.3, 4'-H syn), 7.26 – 7.20 (5 H, m, MC 8'-H; Bn 3,4,5-, 6-H syn), 7.09 (1 
H, t, J 6.7, MC Bn 4-H), 7.01 (2 H, t, J 6.7, MC Bn 3,5-H), 6.78 (1 H, d, J 8.3, 
8'-H syn), 6.69 (1 H, d, J 6.2, 7-H syn), 6.68 – 6.65 (4 H, m, MC Bn 2,6-H; Bn 
2,6-H syn), 6.61 (1 H, t, J 6.2, 5-H syn), 6.29 (1 H, d, J 10.3, 3'-H syn), 6.21 (1 
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H, d, J 6.2, 4-H syn), 4.35 – 4.32 (1 H, m, MC CHHMe), 4.15 – 4.09 (1 H, m, 
MC CHHMe), 4.06 (1 H, d, J 13.7, MC PhCHH), 4.04 (3 H, s, MC NMe), 3.95 
(1 H, d, J 13.7, MC PhCHH), 3.89 – 3.86 (1 H, m, CHHMe syn), 3.75 – 3.72 (1 
H, m, CHHMe syn), 2.70 (3 H, s, NMe syn), 2.55 (1 H, d, J 12.8, PhCHH syn), 
2.52 (1 H, d, J 12.8, PhCHH syn), 1.10 (3 H, t, J 6.5, MC CH2CH3) and 0.81 (3 
H, t, J 6.6, CH2CH3 syn); δC (100 MHz; DMSO-d6); merocyanine: 176.0 (C=N), 
167.4 (C=O), 164.8 (8a'), 149.4 (4'), 143.3 (7a), 140.8 (6'), 134.9 (3a), 132.4 
(Bn 1), 131.3 (6), 131.3 (5), 130.8 (7'), 129.7 (Bn 2,6), 128.4 (Bn 3,5), 128.3 
(Bn 4), 126.8 (5'), 124.7 (4), 121.7 (4a'), 117.9 (8'), 116.2 (7), 115.0 (3'), 66.3 
(3), 64.0 (OCH2), 43.5 (PhCH2), 35.2 (NMe) and 14.1 (CH2CH3); syn 
diastereoisomer: 169.4 (C=O), 158.8 (8a'), 148.4 (7a), 141.3 (6'), 135.7 (Bn 
1), 131.3 (Bn 2,6), 129.1 (6), 128.9 (4'), 128.4 (Bn 3,5), 128.1 (4), 127.5 (Bn 
4), 126.1 (4a), 126.1 (7'), 123.5 (5'), 121.2 (3'), 119.5 (4a'), 118.5 (5), 115.7 
(8'), 107.9 (7), 104.8 (2'), 68.1 (3), 61.1 (OCH2), 34.8 (PhCH2), 28.6 (NMe) 






Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), 4-nitrobenzyl bromide (134 mg, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 1 h to give 
spiropyran 6l (223 mg, 81%) as a yellow powder (purified by precipitation from 





Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), 4-bromobenzyl bromide (155 mg, 0.622 mmol) and 5-
nitrosalicylaldehyde (104 mg, 0.622 mmol) were heated for 1 h to give 
spiropyran 6m (231 mg, 78%) as a yellow powder (purified by precipitation 




Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), allyl bromide (54.0 µL, 0.622 mmol) and 5-nitrosalicylaldehyde (104 
mg, 0.622 mmol) were heated for 2 h to give spiropyran 6n (155 mg, 72%) as 
a yellow powder (purified by precipitation from acetone), spectroscopically 




Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), propargyl bromide (47.0 µL, 0.622 mmol) and 5-nitrosalicylaldehyde 
(104 mg, 0.622 mmol) were heated for 22 h to give spiropyran 6o (144 mg, 67 
%) as a yellow powder (purified by precipitation from acetone), 






Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), phenacyl bromide (124 mg, 0.622 mmol) and 5-nitrosalicylaldehyde 
(104 mg, 0.622 mmol) were heated for 3 h to give spiropyran 6p (202 mg, 
76%) as an amorphous purple film (purified by flash chromatography, eluting 





A microwave reactor tube equipped with a magnetic follower was charged 
with a mixture of 1,2,3-trimethylindole (99.0 mg, 0.622 mmol), benzyl bromide 
(74.0 µL, 0.622 mmol) and salicylaldehyde (195 µL, 1.87 mmol), water (0.5 
mL) and ethanol (0.5 mL) and sealed with a septum cap. The reaction mixture 
was stirred and heated to 150 °C under microwave irradiation (maximum 
power = 300 W), held at 150 °C for 15 minutes, then cooled to room 
temperature and concentrated in vacuo. The resulting crude product was 
purified by flash chromatography, eluting with EtOAc, then 10% MeOH in 
EtOAc, then 50% MeOH in EtOAc, to give spiropyran 6q (141 mg, 64%) as an 
amorphous purple film. νmax = 2967, 2930, 1605, 1484, 1454, 1372, 1235, 
1110, 961, 824, 748 and 700 cm–1; δH (400 MHz; DMSO-d6; 60:10:30 
MC:syn:anti) 8.70 (1 H, d, J 16.5, MC 4'-H), 8.23 (1 H, dd, J 8.0, 1.2, MC 5'-
H), 7.94 (1 H, d, J 7.5, MC 4-H), 7.79 (1 H, d, J 16.5, MC 3'-H), 7.70 (1 H, d, J 
7.5, MC 7-H), 7.60 (1 H, t, J 7.5, MC 5-H), 7.54 (1 H, t, J 7.5, MC 6-H), 7.50 (1 
H, td, J 8.4, 1.2, MC 7'-H), 8.70 (1 H, d, J 16.5, MC 4'-H), 7.20 – 6.97 (16 H, 
m, MC Bn 3,4,5-, 8'-, 6'-H; Bn 3,4,5-H syn; Bn 3,4,5-, 4'-, 5'-, 7'-, 6-H anti), 
6.88 (1 H, t, J 7.2, 6'-H syn), 6.82 (1 H, t, J 7.2, 6'-H anti), 6.80 (1 H, d, J 8.3, 
8'-H syn), 6.76 (1 H, d, J 7.5, 4-H syn), 6.75 (1 H, d, J 10.4, 4'-H syn), 6.64 – 
6.52 (8 H, m, MC Bn 2,6-H; Bn 2,6-H syn; Bn 2,6-, 7-, 8'-H anti), 6.53 (1 H, t, J 
7.3, 5-H anti), 6.52 (1 H, d, J 7.5, 7-H syn), 5.98 (1 H, t, J 7.0, 4-H anti), 5.95 
(1 H, d, J 10.3, 3'-H anti), 5.48 (1 H, d, J 10.2, 3'-H syn), 3.89 (3 H, s, MC 
NMe), 3.79 (1 H, d, J 13.7, MC CHH), 3.65 (1 H, d, J 13.7, MC CHH), 3.16 – 
3.11 (2 H, m, CH2 syn), 2.74 (1 H, d, J 12.4, CHH anti), 2.70 (3 H, s, NMe 
anti), 2.57 (1 H, d, J 12.4, CHH anti), 2.48 (3 H, s, NMe syn), 1.88 (3 H, s, MC 
3-Me), 1.18 (3 H, s, 3-Me syn) and 1.16 (3 H, s, 3-Me anti); δC (100 MHz; 
DMSO-d6) 181.1 (MC C=N), 159.7 (MC 8a'), 154.5 (8a' anti), 153.7(8a' syn), 
149.8 (MC 4'), 148.9 (7a anti), 147.4 (7a syn), 142.7 (MC 7a), 141.3 (MC 3a), 
138.0 (Bn 1 syn), 137.5 (Bn 1 anti), 136.4 (3a syn), 136.1 (MC 7'), 134.9 (3a 
anti), 132.6, 131.7, 131.2, 131.1, 130.3, 130.3, 129.7, 129.4, 129.2, 128.5, 
128.3, 128.2, 128.1, 127.7, 127.6, 127.6, 127.5, 127.4, 126.6, 126.6, 124.4, 
122.4, 121.8, 120.9, 120.7, 120.5, 119.9, 119.6, 119.3, 119.2, 118.8, 118.1, 
117.3, 115.6, 115.1, 114.9, 114.8, 113.2 (MC 3'), 107.4 (7 syn), 107.4 (7 anti), 
105.7 (2 anti), 102.4 (2 syn), 58.1 (MC 3), 56.7 (3 anti), 53.7 (3 syn), 46.1 (MC 
CH2), 41.3 (CH2 anti), 39.0 (CH2 syn), 34.7 (MC NMe), 29.3 (NMe anti), 28.2 
(NMe syn), 25.4 (MC 3-Me), 23.7 (3-Me syn) and 16.9 (3-Me anti); HRMS-





Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 2-hydroxy-1-
naphthaldehyde (107 mg, 0.622 mmol) were heated for 26 h to give 
spiropyran 6r (183 mg, 73%) as an amorphous purple film (purified by flash 
chromatography, eluting with EtOAc, then 5% MeOH in EtOAc, then 50% 
MeOH in EtOAc). νmax = 3072, 3005, 2965, 2880, 1640, 1607, 1482, 1460, 
1360, 1275, 1246, 1169, 1081, 1021, 993, 928, 810, 741 and 701 cm–1; δH 
(400 MHz; DMSO-d6; 30:70 syn:anti) 8.23 (1 H, d, J 8.4, 10'-H anti), 8.16 (1 H, 
d, J 8.4, 10'-H syn), 7.87 (1 H, d, J 10.3, 1'-H anti), 7.85 – 7.81 (2 H, m, 6' and 
7'-H syn), 7.81 (1 H, d, J 8.0, 7'-H anti), 7.72 (1 H, d, J 8.8, 6'-H anti), 7.58 – 
7.52 (3 H, m, 1'-, 9'-H syn; 9'-H anti), 7.39 (1 H, t, J 8.0, 8'-H syn), 7.38 (1 H, t, 
J 8.0, 8'-H anti), 7.21 – 7.13 (7 H, m, 4-, 6-, 5'-H syn; 6-, Bn 3,4,5-H anti), 7.08 
– 7.00 (5 H, m, Bn 2,3,4,5,6-H syn), 6.96 (1 H, d, J 8.8, 5'-H anti), 6.81 (1 H, t, 
J 7.4, 5-H syn), 6.66 (3 H, d, J 7.3, 7-, Bn 2,6-H anti), 6.58 (1 H, t, J 7.3, 5-H 
anti), 6.55 (1 H, J 7.4, 7-H syn), 6.09 (1 H, d, J 10.3, 2'-H anti), 6.04 (1 H, d, J 
7.3, 4-H anti), 5.62 (1 H, d, J 10.2, 2'-H syn), 3.25 (1 H, d, J 13.6, CHH syn), 
3.17 (1 H, d, J 13.6, CHH syn), 2.84 (1 H, d, J 12.3, CHH anti), 2.76 (3 H, s, 
NMe anti), 2.64 (1 H, d, J 12.3, CHH anti), 2.48 (3 H, s, NMe syn), 1.20 (3 H, 
s, 3-Me syn) and 1.15 (3 H, s, 3-Me anti); δC (100 MHz; DMSO-d6); anti 
diastereoisomer: 152.6 (5a'), 148.8 (7a), 137.5 (Bn 1), 132.5 (3a), 131.7 (Bn 
2,6), 130.7 (6'), 129.9 (10a'), 128.9 (6a'), 128.8 (7'), 128.2 (Bn 4), 127.6 (Bn 
3,5), 127.5 (9'), 126.6 (6), 126.1 (1'), 124.7 (4), 124.0 (8'), 121.6 (10'), 118.5 
(2'), 118.2 (5), 117.4 (5'), 111.1 (1a'), 107.4 (7), 105.9 (3'), 56.6 (3), 41.2 
(CH2), 29.4 (NMe) and 17.1 (3-Me); syn diastereoisomer: 151.7 (5a'), 147.3 
(7a), 138.1 (Bn 1), 136.4 (3a), 131.1 (Bn 2,6), 130.7 (6'), 129.9 (10a'), 129.0 
(6a'), 129.0 (7'), 127.7 (Bn 3,5), 127.6 (Bn 4), 127.4 (9'), 126.6 (6), 124.3 (1'), 
124.1 (8'), 122.4 (4), 121.7 (10'), 119.5 (5), 117.5 (2'), 117.4 (5'), 111.7 (1a'), 
107.5 (7), 102.3 (3'), 53.8 (3), 39.0 (CH2), 28.2 (NMe) and 23.8 (3-Me); 




Following the same general method, 1,2,3-trimethylindole (127 mg, 0.798 
mmol), benzyl bromide (95.0 µL, 0.798 mmol) and 5-methoxysalicylaldehyde 
(100 µL, 0.798 mmol) were heated for 6 h to give spiropyran 6s (278 mg, 
91%) as a red powder (purified by precipitation from acetone). νmax = 3024, 
1738, 1585, 1538, 1496, 1475, 1448, 1433, 1372, 1298, 1256, 1233, 1208, 
1161, 1116, 1038, 1021, 968, 817, 752 and 700 cm–1; δH (400 MHz; DMSO-
d6) 8.69 (1 H, d, J 16.3, 4'-H), 7.94 (1 H, d, J 6.6, 4-H), 7.78 (1 H, d, J 16.3, 3'-
H), 7.75 – 7.66 (2 H, m, 5'-, 7-H), 7.63 (1 H, t, J 6.6, 5-H), 7.57 (1 H, t, J 6.6, 
6-H), 7.24 – 7.12 (1 H, m, 7'-H), 7.10 – 7.04 (2 H, m, 8'-, Bn 4-H), 7.04 – 6.97 
(2 H, m, Bn 3,5-H), 6.61 (2 H, d, J 6.1, Bn 2,6-H), 3.91 (3 H, s, NMe), 3.84 (3 
H, s, OMe), 3.82 (1 H, d, J 13.6, CHH), 3.66 (1 H, d, J 13.6, CHH) and 1.93 (3 
H, s, 3-Me); δC (100 MHz; DMSO-d6) 181.0 (C=N), 154.5 (8a'), 153.1 (6'), 
149.7 (4'), 142.7 (7a), 141.3 (3a), 134.9 (Bn 1), 129.7 (6), 129.4 (5), 129.2 (Bn 
2,6), 128.4 (Bn 3,5), 127.7 (Bn 4), 124.3 (4), 124.1 (7'), 121.8 (4a'), 118.4 (8'), 
115.1 (5'), 113.2 (3'), 113.0 (7), 58.1 (3), 56.5 (OMe), 46.1 (CH2), 34.6 (NMe) 






Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 3-ethoxysalicylaldehyde 
(104 mg, 0.622 mmol) were heated for 6 h to give spiropyran 6t (230 mg, 
93%) as an amorphous purple film (purified by flash chromatography, eluting 
with EtOAc, then 50% MeOH in EtOAc). νmax =  3027, 2978, 2930, 1601, 
1579, 1538, 1462, 1393, 1249, 1182, 1078, 1020, 941, 737 and 701 cm–1; δH 
(400 MHz; DMSO-d6; 57:14:29 MC:syn:anti) 8.73 (1 H, d, J 16.4, MC 4'-H), 
7.92 (1 H, d, J 7.5, MC 4-H), 7.78 (1 H, d, J 7.9, MC 5'-H), 7.72 (1 H, d, J 
16.4, MC 3'-H), 7.67 (1 H, d, J 7.4, MC 7-H), 7.59 (1 H, t, J 7.4, MC 5-H), 7.53 
(1 H, t, J 7.5, MC 6-H), 7.20 (1 H, d, J 7.9, MC 7'-H), 7.15 – 7.05 (5 H, m, 6-H 
syn; 6-, Bn 3,4,5-H anti), 7.05 – 7.00 (5 H, m, 5-, Bn 3,4,5-H syn; 4'-H anti), 
7.00 – 6.92 (5 H, m, 4-H anti; MC 6'-, Bn 3,4,5-H), 6.88 (1 H, d, J 7.6, 7'-H 
syn), 6.82 – 6.76 (3 H, m, 6'-H syn; 6'-, 7'-H anti), 6.73 (1 H, d, J 7.8, 5'-H 
anti), 6.72 (1 H, d, J 7.8, 5'-H syn), 6.70 (1 H, d, J 10.2, 4'-H syn), 6.57 (5 H, 
d, J 7.2, 7-, Bn 2,6-H anti; MC Bn 2,6-H), 6.49 (1 H, t, J 7.1, 5-H anti), 6.46 (1 
H, d, J 7.2, 7-H syn), 5.95 (1 H, d, J 7.1, 4-H anti), 5.90 (1 H, d, J 10.2, 3'-H 
anti), 5.43 (1 H, d, J 10.2, 3'-H syn), 4.11 (2 H, q, J 7.0, MC OCH2), 3.91 (2 H, 
q, J 7.0, OCH2 syn), 3.88 (3 H, s, MC NMe), 3.79 (1 H, d, J 14.0, MC CHH), 
3.78 (2 H, q, J 7.0, OCH2 anti), 3.59 (1 H, d, J 14.0, MC CHH), 3.14 (1 H, d, J 
13.3, CHH syn), 3.09 (1 H, d, J 13.3, CHH syn), 2.71 (1 H, d, J 12.4, CHH 
anti), 2.66 (3 H, s, NMe anti), 2.52 (1 H, d, J 12.4, CHH anti), 2.45 (3 H, s, 
NMe syn), 1.89 (3 H, s, MC 3-Me), 1.35 (3 H, t, J 7.0, MC CH2CH3) 1.08 (3 H, 
s, 3-Me syn), 1.07 (3 H, s, 3-Me anti), 1.02 (3 H, t, J 7.0, MC CH2CH3 syn) 
and 0.91 (3 H, t, J 7.0, MC CH2CH3 anti); δC (100 MHz; DMSO-d6) 181.0 (MC 
C=N), 149.5 (MC 8a'), 149.4 (MC 4'), 148.7 (7a anti), 147.8 (MC 8'), 147.3 (7a 
syn), 145.7 (8' syn), 144.4 (8a' anti), 143.7 (8a' syn), 142.6 (MC 7a), 141.2 
(MC 3a), 138.1 (Bn 1 syn), 137.5 (Bn 1 anti), 136.1 (3a syn), 134.8 (MC Bn 1), 
132.6 (3a anti), 131.6 (Bn 2,6 anti), 131.1 (Bn 2,6 syn), 130.3 (4' anti), 129.8 
(MC 6), 129.5 (MC 5), 129.1 (MC Bn 2,6), 128.4 (4' syn), 128.3 (MC Bn 4), 
128.1 (6 anti), 127.7, 127.7, 127.5, 126.6, 126.5, 125.5 (4 anti), 124.3 (MC 4), 
122.5, 122.1 (MC 4a'), 121.5 (MC 5'), 120.6, 120.5, 120.4, 120.3, 120.3, 120.2 
(MC 6'), 120.0 (3' anti), 119.2 (5' syn), 118.9 (3' syn), 118.2 (MC 7'), 117.9 (5 
anti), 117.3 (7' syn), 117.2 (7' anti), 115.1 (MC 7), 113.3 (MC 3'), 107.2 (7 
syn), 107.2 (7 anti), 105.5 (2 anti), 102.2 (2 syn), 65.4 (OCH2 syn), 65.1 
(OCH2 anti), 65.0 (MC OCH2), 58.1 (MC 3), 56.4 (3 anti), 53.7 (3 syn), 46.1 
(MC Bn CH2), 41.5 (Bn CH2 anti), 39.2 (Bn CH2 syn), 34.7 (MC NMe), 29.3 
(NMe anti), 28.1 (NMe syn), 25.4 (MC 3-Me), 23.6 (3-Me syn), 16.8 (3-Me 
anti), 15.2 (CH2CH3 syn), 15.0 (CH2CH3 anti) and 14.9 (MC CH2CH3); HRMS-





Following the same general method, 1,2,3-trimethylindole (64.0 mg, 0.400 
mmol), benzyl bromide (48.0 µL, 0.400 mmol) and methyl 3-formyl-4-
hydroxybenzoate (112 mg, 0.400 mmol) were heated for 1 h to give 
 20 
spiropyran 6u (136 mg, 83%) as a yellow powder (purified by precipitation 




Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-bromosalicylaldehyde 
(125 mg, 0.622 mmol) were heated for 4 h to give spiropyran 6v (174 mg, 
65%) as a yellow powder (purified by precipitation from acetone), 




Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 4-bromosalicylaldehyde 
(125 mg, 0.622 mmol) were heated for 4 h to give spiropyran 6w (158 mg, 
59%) as an orange powder (purified by precipitation from acetone). νmax = 
2980, 1588, 1537, 1475, 1452, 1419, 1371, 1297, 1243, 1113, 1071, 1022, 
967, 939, 906, 853, 787, 753 and 701 cm–1; δH (400 MHz; DMSO-d6) 8.58 (1 
H, d, J 15.6, 4'-H), 8.15 (1 H, br s, 5'-H), 7.92 (1 H, br s, 4-H), 7.81 (1 H, d, J 
15.6, 3'-H), 7.70 (1 H, br s, 7-H), 7.62 – 7.50 (2 H, m, 5-, 6-H), 7.32 (1 H, s, 8'-
H), 7.26 (1 H, br s, 6'-H), 7.12 – 6.92 (3 H, m, Bn 3,4,5-H), 6.61 (2 H, br s, Bn 
2,6-H), 3.92 (3 H, s, NMe), 3.76 (1 H, d, J 13.5, CHH), 3.63 (1 H, d, J 13.5, 
CHH) and 1.96 (3 H, s, 3-Me); δC (100 MHz; DMSO-d6) 181.1 (C=N), 160.0 
(8a'), 148.6 (4'), 142.7 (7a), 141.4 (3a), 134.9 (Bn 1), 132.7 (5'), 129.8 (6), 
129.6 (5), 129.2 (Bn 2,6), 128.9 (7'), 128.3 (Bn 3,5), 127.7 (Bn 4), 124.4 (4), 
123.6 (6'), 121.3 (4a'), 119.9 (8'), 115.3 (7), 113.9 (3'), 58.2 (3), 45.9 (CH2), 
34.7 (NMe) and 25.2 (3-Me); HRMS-ES+ (m/z): Found:  432.0968 (MH+, 
C25H23




Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 5-chlorosalicylaldehyde 
(97.0 mg, 0.622 mmol) were heated for 1.5 h to give spiropyran 6x (209 mg, 
87%) as a yellow powder (purified by precipitation from acetone). νmax = 2983, 
1652, 1558, 1474, 1456, 1365, 1217, 1028, 1007, 826, 765 and 668 cm–1; δH 
(400 MHz; DMSO-d6) 8.58 (1 H, d, J 16.5, 4'-H), 8.31 (1 H, s, 5'-H), 7.92 (1 H, 
d, J 7.3, 4-H), 7.83 (1 H, d, J 16.5, 3'-H), 7.72 (1 H, d, J 7.2, 7-H), 7.65 (1 H, t, 
J 7.3, 5-H), 7.58 (1 H, t, J 7.3, 6-H), 7.53 (1 H, d, J 8.3, 7'-H), 7.11 (1 H, d, J 
8.3, 8'-H), 7.08 – 6.99 (3 H, m, Bn 3,4,5-H), 6.61 (2 H, d, J 7.2, Bn 2,6-H), 
3.89 (3 H, s, NMe), 3.78 (1 H, d, J 13.7, CHH), 3.66 (1 H, d, J 13.3, CHH) and 
1.92 (3 H, s, 3-Me); δC (100 MHz; DMSO-d6) 181.2 (C=N), 158.3 (8a'), 148.0 
(4'), 142.7 (7a), 141.5 (3a), 135.1 (7'), 134.8 (Bn 1), 129.8 (5), 129.8 (6), 
129.7 (5'), 129.2 (Bn 2,6), 128.4 (Bn 3,5), 127.7 (Bn 4), 124.4 (6'), 124.3 (4a'), 
123.2 (4), 119.0 (8'), 115.3 (7), 114.5 (3'), 58.3 (3), 45.9 (CH2), 34.7 (NMe) 







Following the same general method, 1,2,3-trimethylindole (99.0 mg, 0.622 
mmol), benzyl bromide (74.0 µL, 0.622 mmol) and 6-chlorosalicylaldehyde 
(97.0 mg, 0.622 mmol) were heated for 1 h to give spiropyran 6y (200 mg, 
83%) as a yellow powder (purified by precipitation from acetone). νmax = 2984, 
1586, 1539, 1472, 1448, 1388, 1311, 1282, 1268, 1231, 1162, 1129, 1078, 
1021, 971, 939, 911, 853, 782, 752 and 703 cm–1; δH (400 MHz; DMSO-d6) 
8.59 (1 H, d, J 16.3, 4'-H), 8.07 (1 H, d, J 16.3, 3'-H), 7.96 (1 H, d, J 7.5, 4-H), 
7.78 (1 H, d, J 7.5, 7-H), 7.67 (1 H, t, J 7.5, 5-H), 7.60 (1 H, t, J 7.5, 6-H), 7.48 
(1 H, t, J 8.0, 7'-H), 7.20 (1 H, d, J 8.0, 6'-H), 7.14 (1 H, d, J 8.0, 8'-H), 7.09 – 
7.01 (3 H, m, Bn 3,4,5-H), 6.66 (2 H, d, J 6.9, Bn 2,6-H), 3.86 (3 H, s, NMe), 
3.81 (1 H, d, J 13.3, CHH), 3.61 (1 H, d, J 13.3, CHH) and 1.95 (3 H, s, 3-Me); 
δC (100 MHz; DMSO-d6) 181.7 (C=N), 161.3 (8a'), 147.1 (4'), 142.7 (7a), 
141.5 (3a), 137.0 (5'), 135.3 (7'), 134.7 (Bn 1), 129.9 (5), 129.8 (6), 129.3 (Bn 
2,6), 128.4 (Bn 3,5), 127.8 (Bn 4), 124.5 (4), 121.5 (6'), 119.2 (4a'), 118.0 (3'), 
116.6 (8'), 115.5 (7), 58.2 (3), 46.1 (CH2), 34.7 (NMe) and 25.2 (3-Me); 
HRMS-ES+ (m/z): Found:  388.1528 (MH+, C25H23
35ClNO requires: 388.1468). 
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